pamidronate has been researched along with Kidney Failure, Chronic in 29 studies
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Secondary hyperparathyroidism may worsen after the administration of pamidronate in postmenopausal hemodialysis (HD) patients." | 9.16 | Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism. ( Chu, P; Huang, CY; Lo, L; Lu, KC; Wu, CC; Zheng, CM, 2012) |
| "The aim of this study was to evaluate the efficacy and safety of pamidronate in HD patients affected by severe secondary hyperparathyroidism and moderate hypercalcemia who were receiving intravenous calcitriol (Calcijex)." | 9.10 | Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. ( Fuster, D; Mas, M; Moreno, A; Torregrosa, JV; Ybarra, J, 2003) |
| " We report a case in which a patient with tertiary hyperparathyroidism and refractory hypercalcemia who was not a surgical candidate was managed with the bisphosphonate pamidronate." | 7.75 | Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient. ( Canada, RB; Czosnowski, LM; Hudson, JQ, 2009) |
| "The purpose of this study is to evaluate the acute effect of pamidronate on plasma ionized calcium (iCa) level reduction and dynamic parathyroid hormone (PTH) secretion in postmenopausal hemodialysis-dependent women with secondary hyperparathyroidism." | 7.72 | Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. ( Chu, P; Lin, SH; Lin, YF; Lu, KC; Yeung, LK, 2003) |
| "Pamidronate 30 mg was given intravenously every 3 months after LT for the duration of 1 year to 43 patients with osteopenia or osteoporosis prior LT." | 6.73 | Pamidronate and osteoporosis prevention in liver transplant recipients. ( Fiore, CE; Giostra, E; Mentha, G; Pennisi, P; Rizzoli, R; Trombetti, A, 2007) |
| "BACKGROUND Hypercalcemia is a common complication in the intensive care unit (ICU)." | 5.48 | Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report. ( El Madhoun, I; El Zeer, HS; Khatib, M; Mahmoud, S; Mitwally, H, 2018) |
| "Secondary hyperparathyroidism may worsen after the administration of pamidronate in postmenopausal hemodialysis (HD) patients." | 5.16 | Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism. ( Chu, P; Huang, CY; Lo, L; Lu, KC; Wu, CC; Zheng, CM, 2012) |
| "The aim of this study was to evaluate the efficacy and safety of pamidronate in HD patients affected by severe secondary hyperparathyroidism and moderate hypercalcemia who were receiving intravenous calcitriol (Calcijex)." | 5.10 | Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. ( Fuster, D; Mas, M; Moreno, A; Torregrosa, JV; Ybarra, J, 2003) |
| " Calciphylaxis process started when she received calcium gluconate intravenously the day before the surgery to correct hypocalcemia and continued progressively despite peritoneal dialysis and forced stopping calcium-containing medication." | 3.81 | Successful treatment of calciphylaxis with pamidronate. ( Hooman, N; Jahangiri, F; Mehrazma, M; Naghshi-Zadiyan, R, 2015) |
| " We report a case in which a patient with tertiary hyperparathyroidism and refractory hypercalcemia who was not a surgical candidate was managed with the bisphosphonate pamidronate." | 3.75 | Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient. ( Canada, RB; Czosnowski, LM; Hudson, JQ, 2009) |
| "The purpose of this study is to evaluate the acute effect of pamidronate on plasma ionized calcium (iCa) level reduction and dynamic parathyroid hormone (PTH) secretion in postmenopausal hemodialysis-dependent women with secondary hyperparathyroidism." | 3.72 | Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. ( Chu, P; Lin, SH; Lin, YF; Lu, KC; Yeung, LK, 2003) |
| "The successful use of pamidronate, a bisphosphonate, for the treatment of hypercalcemia and/or osteopenia is reported in three children with renal failure or following renal transplant." | 3.70 | The use of pamidronate in three children with renal disease. ( Rodd, C; Sellers, E; Sharma, A, 1998) |
| " Immunosuppression was cyclosporine and prednisolone, with no difference in dosing between the 2 groups." | 2.74 | Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. ( Altmann, P; Andrews, C; Banks, LM; Cockwell, P; Cunningham, J; Dudley, C; Hall-Craggs, M; Noonan, K; Pattison, J; Sweny, P; Walsh, SB; Wilkie, M; Yaqoob, MM, 2009) |
| "Pamidronate 30 mg was given intravenously every 3 months after LT for the duration of 1 year to 43 patients with osteopenia or osteoporosis prior LT." | 2.73 | Pamidronate and osteoporosis prevention in liver transplant recipients. ( Fiore, CE; Giostra, E; Mentha, G; Pennisi, P; Rizzoli, R; Trombetti, A, 2007) |
| "Pamidronate treatment was associated with development of adynamic bone histology." | 2.71 | Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. ( Bognar, I; Burris, L; Coco, M; Durkin, P; Faugere, MC; Figueroa, K; Glicklich, D; Greenstein, S; Malluche, H; McDonough, P; Schechner, R; Tellis, V; Wang, G, 2003) |
| "Very rapid bone loss, osteopenia and skeletal morbidity after renal transplantation have been well documented and found to occur in a sex dependent fashion." | 2.69 | Pamidronate therapy as prevention of bone loss following renal transplantation. ( Almond, MK; Ball, E; Cunningham, J; Evans, K; Fan, SL, 2000) |
| "Collapsing focal segmental glomerulosclerosis is well described in its idiopathic form, mostly seen in young African American patients, and in association with HIV virus." | 2.45 | [Bisphosphonate-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review]. ( Jotterand, V; Martin, PY; Moll, S; Saudan, P, 2009) |
| "Hypocalcemia was treated with calcium and vitamin D3 supplements." | 2.44 | [Zoledronate-associated end stage renal failure and hypocalcaemia]. ( Bodmer, M; Kummer, O; Ramazzina, C; Rätz Bravo, AE; Zysset Aschmann, Y, 2007) |
| "BACKGROUND Hypercalcemia is a common complication in the intensive care unit (ICU)." | 1.48 | Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report. ( El Madhoun, I; El Zeer, HS; Khatib, M; Mahmoud, S; Mitwally, H, 2018) |
| "Calciphylaxis is an infrequent disease that almost exclusively affects patients with chronic kidney disease, although cases have been observed in patients without renal function impairment." | 1.48 | Sodium thiosulfate and pamidronate for treatment of calciphylaxis: case report. ( Alvarez, CL; Estifan Ksabji, J; Fernández Cañabate, S; Ortega Valin, L, 2018) |
| "Calciphylaxis is a rare complication of chronic renal failure mostly with poor prognosis." | 1.36 | Skin wounds associated with calciphylaxis in end-stage renal disease patients on dialysis. ( Sulková, SD; Válek, M, 2010) |
| "In the distal femur, a high-turnover renal osteodystrophy was found but pamidronate suppressed this bone turnover and increased bone mineral content." | 1.35 | Treatment of experimental renal osteodystrophy with pamidronate. ( Iwaniec, UT; Järvinen, TL; Jokihaara, J; Jolma, PM; Kannus, P; Kööbi, P; Mustonen, JT; Pörsti, IH; Saha, HH; Sievänen, H; Turner, RT, 2008) |
| "The pamidronate dose was increased to 60 mg once a week and was well tolerated." | 1.32 | Pamidronate in a girl with chronic renal insufficiency dependent on parenteral nutrition. ( Chesney, RW; Duke, JL; Frizzell, NK; Hak, EB; Jones, DP, 2003) |
| "Pamidronate was given to 10 patients with end stage renal failure who had become symptomatically hypercalcaemic due to the use of calcium based phosphate binders and alphacalcidol." | 1.29 | Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure. ( Davenport, A; Goel, S; Mackenzie, JC, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (17.24) | 18.2507 |
| 2000's | 17 (58.62) | 29.6817 |
| 2010's | 7 (24.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, N | 1 |
| Reilly, RF | 1 |
| Mahmoud, S | 1 |
| Mitwally, H | 1 |
| El Zeer, HS | 1 |
| El Madhoun, I | 1 |
| Khatib, M | 1 |
| Akhtar, J | 1 |
| Gorantla, VK | 1 |
| Snell, PD | 1 |
| Wall, BM | 1 |
| Fernández Cañabate, S | 1 |
| Alvarez, CL | 1 |
| Ortega Valin, L | 1 |
| Estifan Ksabji, J | 1 |
| Huang, CY | 1 |
| Zheng, CM | 1 |
| Wu, CC | 1 |
| Lo, L | 1 |
| Lu, KC | 2 |
| Chu, P | 2 |
| Hooman, N | 1 |
| Naghshi-Zadiyan, R | 1 |
| Mehrazma, M | 1 |
| Jahangiri, F | 1 |
| Jotterand, V | 1 |
| Moll, S | 1 |
| Martin, PY | 1 |
| Saudan, P | 1 |
| Czosnowski, LM | 1 |
| Hudson, JQ | 1 |
| Canada, RB | 1 |
| Walsh, SB | 1 |
| Altmann, P | 1 |
| Pattison, J | 1 |
| Wilkie, M | 1 |
| Yaqoob, MM | 1 |
| Dudley, C | 1 |
| Cockwell, P | 1 |
| Sweny, P | 1 |
| Banks, LM | 1 |
| Hall-Craggs, M | 1 |
| Noonan, K | 1 |
| Andrews, C | 1 |
| Cunningham, J | 2 |
| Sulková, SD | 1 |
| Válek, M | 1 |
| Saghafi, D | 1 |
| Suzuki, Y | 3 |
| Kuriyama, S | 1 |
| Atsumi, Y | 1 |
| Murata, C | 1 |
| Matsuoka, K | 1 |
| Taniyama, M | 1 |
| Muramatsu, T | 1 |
| Ohta, S | 1 |
| Duke, JL | 1 |
| Jones, DP | 1 |
| Frizzell, NK | 1 |
| Chesney, RW | 1 |
| Hak, EB | 1 |
| Torregrosa, JV | 1 |
| Moreno, A | 1 |
| Mas, M | 1 |
| Ybarra, J | 1 |
| Fuster, D | 1 |
| Coco, M | 1 |
| Glicklich, D | 1 |
| Faugere, MC | 1 |
| Burris, L | 1 |
| Bognar, I | 1 |
| Durkin, P | 1 |
| Tellis, V | 1 |
| Greenstein, S | 1 |
| Schechner, R | 1 |
| Figueroa, K | 1 |
| McDonough, P | 1 |
| Wang, G | 1 |
| Malluche, H | 1 |
| Yeung, LK | 1 |
| Lin, SH | 2 |
| Lin, YF | 1 |
| Monney, P | 1 |
| Nguyen, QV | 1 |
| Perroud, H | 1 |
| Descombes, E | 1 |
| Cheng, CJ | 1 |
| Chou, CH | 1 |
| Trimarchi, H | 1 |
| Lombi, F | 1 |
| Forrester, M | 1 |
| Elizondo, C | 1 |
| Sawinski, D | 1 |
| Pereyra, H | 1 |
| Freixas, E | 1 |
| Pennisi, P | 1 |
| Trombetti, A | 1 |
| Giostra, E | 1 |
| Mentha, G | 1 |
| Rizzoli, R | 1 |
| Fiore, CE | 1 |
| Ramazzina, C | 1 |
| Zysset Aschmann, Y | 1 |
| Kummer, O | 1 |
| Rätz Bravo, AE | 1 |
| Bodmer, M | 1 |
| Jokihaara, J | 1 |
| Pörsti, IH | 1 |
| Kööbi, P | 1 |
| Jolma, PM | 1 |
| Mustonen, JT | 1 |
| Saha, HH | 1 |
| Sievänen, H | 1 |
| Kannus, P | 1 |
| Iwaniec, UT | 1 |
| Turner, RT | 1 |
| Järvinen, TL | 1 |
| Garnero, P | 1 |
| Grimaux, M | 1 |
| Seguin, P | 1 |
| Delmas, PD | 1 |
| Davenport, A | 1 |
| Goel, S | 1 |
| Mackenzie, JC | 1 |
| Sinha, RN | 1 |
| Fraser, WD | 1 |
| Casson, IF | 1 |
| Sellers, E | 1 |
| Sharma, A | 1 |
| Rodd, C | 1 |
| Fan, SL | 1 |
| Almond, MK | 1 |
| Ball, E | 1 |
| Evans, K | 1 |
| Svendsen, OL | 1 |
| Yap, AS | 1 |
| Hockings, GI | 1 |
| Fleming, SJ | 1 |
| Khafagi, FA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 2 Year Prospective, Multicentre, Open-label, Randomised, Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients (With a PTH > 150pg/ml) on a Ciclosporin A and Glucocorticoid B[NCT00738257] | Phase 4 | 126 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for pamidronate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Hungry bone syndrome.
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; Calcium; Diphosphonates; Hum | 2017 |
[Bisphosphonate-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Female; Fractures, Spontaneous | 2009 |
[Zoledronate-associated end stage renal failure and hypocalcaemia].
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; | 2007 |
6 trials available for pamidronate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Topics: Anti-Inflammatory Agents; Bone Density Conservation Agents; Calcitriol; Calcium; Calcium Channel Ago | 2012 |
Effect of pamidronate on bone loss after kidney transplantation: a randomized trial.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Bone Density Conservation Agents; Bone Resorption; | 2009 |
Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis.
Topics: Aged; Bone Density; Diphosphonates; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; K | 2003 |
Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate.
Topics: Adult; Anti-Inflammatory Agents; Biopsy; Bone Density; Diphosphonates; Female; Hormones; Humans; Imm | 2003 |
Pamidronate and osteoporosis prevention in liver transplant recipients.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Diphosphona | 2007 |
Pamidronate therapy as prevention of bone loss following renal transplantation.
Topics: Absorptiometry, Photon; Adult; Aged; Alkaline Phosphatase; Aluminum; Anti-Inflammatory Agents; Bone | 2000 |
20 other studies available for pamidronate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Female; Humans; Hypercalcemia; K | 2018 |
Acute esophageal necrosis (black esophagus) complicating calcific uremic arteriolopathy
.
Topics: Acute Disease; Aged; Arterioles; Bone Density Conservation Agents; Esophagitis; Esophagoscopy; Esoph | 2019 |
Sodium thiosulfate and pamidronate for treatment of calciphylaxis: case report.
Topics: Administration, Intravenous; Aged; Calciphylaxis; Chelating Agents; Drug Therapy, Combination; Femal | 2018 |
Successful treatment of calciphylaxis with pamidronate.
Topics: Biopsy; Calciphylaxis; Calcium Gluconate; Debridement; Diphosphonates; Female; Humans; Hypocalcemia; | 2015 |
Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient.
Topics: Aged; Calcium; Diphosphonates; Humans; Hypercalcemia; Hyperparathyroidism; Kidney Failure, Chronic; | 2009 |
Skin wounds associated with calciphylaxis in end-stage renal disease patients on dialysis.
Topics: Aged; Anti-Inflammatory Agents; Calciphylaxis; Cinacalcet; Diphosphonates; Female; Humans; Hyperpara | 2010 |
Use of bisphosphonates in patients with myeloma and renal failure.
Topics: Antineoplastic Agents; Bone Remodeling; Chronic Kidney Disease-Mineral and Bone Disorder; Contraindi | 2003 |
Maternal inheritance of diabetes is associated with inactive ALDH2 genotype in diabetics with renal failure in Japanese.
Topics: Adult; Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Body Mass Index; Diabeti | 2003 |
Pamidronate in a girl with chronic renal insufficiency dependent on parenteral nutrition.
Topics: Anti-Inflammatory Agents; Calcitonin; Child; Chlorothiazide; Colonic Diseases; Diphosphonates; Diure | 2003 |
Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Topics: Aged; Chronic Kidney Disease-Mineral and Bone Disorder; Diphosphonates; Female; Humans; Hypercalcemi | 2003 |
Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure.
Topics: Anti-Inflammatory Agents; C-Reactive Protein; Calciphylaxis; Diphosphonates; Female; Humans; Infusio | 2004 |
An unrecognized cause of recurrent hypercalcemia: immobilization.
Topics: Aged; Bone Density Conservation Agents; Calcium; Diphosphonates; Exercise Therapy; Gout; Humans; Hyp | 2006 |
Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient.
Topics: Antineoplastic Agents; Diphosphonates; Humans; Hypercalcemia; Kidney Failure, Chronic; Male; Middle | 2006 |
Treatment of experimental renal osteodystrophy with pamidronate.
Topics: Animals; Bone Demineralization, Pathologic; Bone Density; Bone Remodeling; Chronic Kidney Disease-Mi | 2008 |
Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro.
Topics: Adult; Antibodies, Monoclonal; Bone Diseases, Metabolic; Bone Neoplasms; Cell Line; Diphosphonates; | 1994 |
Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure.
Topics: Calcium Carbonate; Diphosphonates; Female; Humans; Hydroxycholecalciferols; Hypercalcemia; Kidney Fa | 1993 |
Long-term management of hypercalcaemia in chronically active sarcoidosis.
Topics: Adult; Chronic Disease; Diphosphonates; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Hy | 1997 |
The use of pamidronate in three children with renal disease.
Topics: Adolescent; Anti-Inflammatory Agents; Bone Density; Bone Diseases, Metabolic; Child; Diphosphonates; | 1998 |
Statistical error in pamidronate study?
Topics: Anti-Inflammatory Agents; Diphosphonates; Humans; Kidney Failure, Chronic; Kidney Transplantation; P | 2000 |
Use of aminohydroxypropylidene bisphosphonate (AHPrBP, "APD") for the treatment of hypercalcemia in patients with renal impairment.
Topics: Acute Kidney Injury; Adult; Diphosphonates; Female; Humans; Hypercalcemia; Kidney Failure, Chronic; | 1990 |